NASDAQ:VCEL - Vericel Stock Price, Forecast & News

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel Corp (NASDAQ:VCEL) announced its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.02) by $0.09. The biotechnology company earned $30.50 million during the quarter, compared to analyst estimates of $26.84 million. Vericel had a positive return on equity of 3.66% and a negative net margin of 12.68%. The firm's quarterly revenue was up 35.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.02) EPS. View Vericel's Earnings History.

Vericel is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Vericel.

4 Wall Street analysts have issued 12 month price targets for Vericel's stock. Their forecasts range from $17.92 to $32.00. On average, they anticipate Vericel's share price to reach $23.23 in the next year. This suggests a possible upside of 33.0% from the stock's current price. View Analyst Price Targets for Vericel.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vericel.

News stories about VCEL stock have trended positive this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vericel earned a news impact score of 3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Vericel.

Some companies that are related to Vericel include Allogene Therapeutics (ALLO), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Cortexyme (CRTX), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Alector (ALEC), Orchard Therapeutics (ORTX) and Coherus Biosciences (CHRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Momo (MOMO), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Amarin (AMRN), Dynavax Technologies (DVAX), NVIDIA (NVDA), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX) and Verastem (VSTM).

Vericel's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Calamos Advisors LLC (0.48%), Roubaix Capital LLC (0.15%) and Ingalls & Snyder LLC (0.13%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman. View Institutional Ownership Trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC and Ingalls & Snyder LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, Michael Halpin and Steven C Gilman. View Insider Buying and Selling for Vericel.

VCEL stock was bought by a variety of institutional investors in the last quarter, including Roubaix Capital LLC. View Insider Buying and Selling for Vericel.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $17.47.

Vericel has a market capitalization of $780.73 million and generates $90.86 million in revenue each year. The biotechnology company earns $-8,140,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Vericel employs 216 workers across the globe.View Additional Information About Vericel.

The official website for Vericel is http://www.vcel.com/.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]